Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Nadia Raban"'
Autor:
Félix Blanc-Durand, Elisa Yaniz-Galende, Alba Llop-Guevara, Catherine Genestie, Violeta Serra, Andrea Herencia-Ropero, Christophe Klein, Dominique Berton, Alain Lortholary, Nadine Dohollou, Christophe Desauw, Michel Fabbro, Emmanuelle Malaurie, Nathalie Bonichon-Lamaichhane, Coraline Dubot, Jean Emmanuel Kurtz, Gaëtan de Rauglaudre, Nadia Raban, Annick Chevalier-Place, Gwenael Ferron, Marie-Christine Kaminsky, Claire Kramer, Etienne Rouleau, Alexandra Leary
Publikováno v:
Gynecologic Oncology. 171:106-113
Autor:
Florence Joly, Michel Fabbro, Dominique Berton, Justine Lequesne, Amélie Anota, Alicja Puszkiel, Anne Floquet, Hélène Vegas, Hugues Bourgeois, Leïla Bengrine Lefevre, Benoît You, Fanny Pommeret, Alain Lortholary, Dominique Spaeth, Anne-Claire Hardy-Bessard, Cyril Abdeddaim, Marie-Christine Kaminsky-Forrett, Michel Tod, Jean-Emmanuel Kurtz, Francesco Del Piano, Jérôme Meunier, Nadia Raban, Jérome Alexandre, Marie-Ange Mouret-Reynier, Isabelle Ray-Coquard, Magali Provansal Gross, Pierre-Emmanuel Brachet
Publikováno v:
Gynecologic Oncology
Gynecologic Oncology, 2022, 166 (3), pp.389-396. ⟨10.1016/j.ygyno.2022.06.022⟩
Gynecologic Oncology, 2022, 166 (3), pp.389-396. ⟨10.1016/j.ygyno.2022.06.022⟩
Anti-angiogenic rechallenge with bevacizumab plus chemotherapy is effective in recurrent ovarian cancer (rOC); however, data are limited on tyrosine kinase inhibitors after progression on maintenance bevacizumab.In the randomized phase II TAPAZ trial
Autor:
Jean Emmanuel Kurtz, Amélie Anota, Claire Cropet, Frank Priou, Philipp Harter, Sandro Pignata, Isabel Palacio, Edgar Petru, Hiroaki Kobayashi, Peter Vuylsteke, Gabriella Parma, Johanna Mäenpää, Eric Raymond, Paul Buderath, Domenica Lorusso, Ana Herrero, Nadia Raban, Eric Pujade-Lauraine, Florence Joly, Isabelle Laure Ray-Coquard
Publikováno v:
Journal of Clinical Oncology. 40:5560-5560
5560 Background: In the Phase III PAOLA-1/ENGOT-ov25 trial, maintenance olaparib + bevacizumab (bev) provided a significant progression-free survival (PFS) benefit vs placebo (pbo) + bev in patients (pts) with newly diagnosed advanced ovarian cancer
Autor:
Felix Blanc-Durand, Elisa Yaniz-Galende, Catherine Genestie, Hortense Gauthier De Saint Basile, Laure Chardin, Gaetan De Rauglaudre, Nadia Raban, Annick Chevalier, Gwenael Ferron, Marie-Christine Kaminsky, Isabelle Laure Ray-Coquard, Salima Hamizi, Pierre Combe, Sophie Abadie Lacourtoisie, Florence Joly, Jérome Meunier, Anne Floquet, Jérôme Alexandre, Audrey Le Formal, Alexandra Leary
Publikováno v:
Journal of Clinical Oncology. 40:5554-5554
5554 Background: Antibodies targeting PDL1 or PD1 have been disappointing so far in the treatment of ovarian cancer (OC). A greater understanding of the complex iTME and of the impact of chemotherapy on immune features could uncover promising immune
Autor:
Jacobus Pfisterer, Catherine M Shannon, Klaus Baumann, Joern Rau, Philipp Harter, Florence Joly, Jalid Sehouli, Ulrich Canzler, Barbara Schmalfeldt, Andrew P Dean, Alexander Hein, Alain G Zeimet, Lars C Hanker, Thierry Petit, Frederik Marmé, Ahmed El-Balat, Rosalind Glasspool, Nikolaus de Gregorio, Sven Mahner, Tarek M Meniawy, Tjoung-Won Park-Simon, Marie-Ange Mouret-Reynier, Cristina Costan, Werner Meier, Alexander Reinthaller, Jeffrey C Goh, Tifenn L'Haridon, Sally Baron Hay, Stefan Kommoss, Andreas du Bois, Jean-Emmanuel Kurtz, Sven Ackermann, Christoph Anthuber, Mustafa Aydogdu, Angelika Baldauf, Wolfgang Bauer, Dirk Behringer, Antje Belau, Alexandra Bender, Cosima Brucker, Alexander Burges, Trygve Daabach, Dominik Denschlag, Mustafa Deryal, Steffen Dörfel, Juliane Ebert, Tanja Fehm, Susanne Maria Feidicker, Gabriele Feisel-Schwickardi, Ricardo Felberbaum, Matthias Frank, Gerhard Gebauer, Bernd Gerber, Axel Gerhardt, Andrea Grafe, Martin Griesshammer, Eva-Maria Grischke, Isolde Gröll, Martina Gropp-Meier, Dietrich Hager, Volker Hanf, Carla Verena Hannig, Peer Hantschmann, Tanja Hauzenberger, Uwe Herwig, Martin Heubner, Carsten Hielscher, Felix Hilpert, Thomas Hitschold, Manfred Hofmann, Christian Jackisch, Wolfgang Janni, Ludwig Kiesel, Yon-Dschun Ko, Hans-Joachim Koch, Petra Krabisch, Peter Krieger, Thomas Kubin, Thorsten Kühn, Björn Lampe, Peter Ledwon, Sabine Lemster, Benno Lex, Clemens Liebrich, Ralf Lorenz, Hans-Joachim Lück, Peter Mallmann, Wolfgang Meinerz, Götz Menke, Volker Möbus, Thomas Müller, Volker Müller, Tanja Neunhöffer, Angelika Ober, Gülten Oskay-Özcelik, Horst Ostertag, Martin Pölcher, Beate Rautenberg, Daniel Rein, Wilhelm Reiter, Andreas Rempen, Ingo Runnebaum, Marcus Schmidt, Sabine Schnohr, Heinz Scholz, Willibald Schröder, Eike Simon, Antje Sperfeld, Annette Steckkönig, Hans-Georg Strauß, Ronaldo Stuth, Jürgen Terhaag, Falk Thiel, Marc Thill, Oliver Tomé, Christoph Uleer, Susanne Vogel, Hermann Voß, Michael Weigel, Ulrich Winkler, Arthur Wischnik, Tobias Zeiser, Andreas Zorr, Ros Glasspool, Emma Hudson, Rachel Jones, Judith Lafleur, Christian Marth, Edgar Petru, Yoland Antill, Mary Azer, Sally Baron-Hay, Philip Beale, Stephen Begbie, Allison Black, Karen Briscoe, Andrew Dean, Jeffrey Goh, Sandra Harvey, Chee Lee, Marco Matos, Tarek Meniawy, Inger Olesen, Catherine Shannon, Paul Vasey, Sophie Abadie-Lacourtoisie, Olivier Arsene, Sophie Barthier, Célia Becuwe-Roemer, Dominique Berton-Rigaud, Maria Cappiello-Bataller, Stéphanie Catala, Francesco Del Piano, Gaël Deplanque, Raymond Despax, Nadine Dohollou, Claire Garnier-Tixidré, Julien Grenier, Emmanuel Guardiola, Anne-Claire Hardy-Bessard, Claudia Lefeuvre-Plesse, Marianne Leheurteur, Anne Lesoin, Charles-Briac Levache, Raffaele Longo, Alain Lortholary, Jérôme Meunier, Nadia Raban, Olivier Romano, Jean-Michel Vannetzel, Alain Zannetti
Publikováno v:
Lancet Oncology
Lancet Oncology, 2020, 21 (5), pp.699-709. ⟨10.1016/S1470-2045(20)30142-X⟩
The Lancet Oncology
The Lancet Oncology, 2020, 21 (5), pp.699-709. ⟨10.1016/S1470-2045(20)30142-X⟩
Lancet Oncology, 2020, 21 (5), pp.699-709. ⟨10.1016/S1470-2045(20)30142-X⟩
The Lancet Oncology
The Lancet Oncology, 2020, 21 (5), pp.699-709. ⟨10.1016/S1470-2045(20)30142-X⟩
Background:\ud State-of-the art therapy for recurrent ovarian cancer suitable for platinum-based re-treatment includes bevacizumab-containing combinations (eg, bevacizumab combined with carboplatin–paclitaxel or carboplatin–gemcitabine) or the mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6dcdfeb9666bdc098f5e231578e0974
https://hal.science/hal-02887894
https://hal.science/hal-02887894